Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin.
Pseudomonas aeruginosa (PA) is the main cause of morbidity and mortality in cystic fibrosis (CF) patients. CF patients with chronic PA infections have a more rapid deterioration of their lung function and the bacteria become impossible to eradicate from the lungs. Antibiotic resistance among PA strains in CF patients is steadily increasing. Specific chicken (IgY) antibodies against PA have been shown to have potential to prevent PA infections in CF. Anti-Pseudomonas IgY reduces PA adhesion to epithelia, but the mechanism has not been fully elucidated. To gain further insight into the prophylactic effect of these antibodies, the immunoreactivity was investigated by 2D electrophoresis of PA strains, immunoblotting and MALDI-TOF-MS. To confirm the identity of the proteins, the tryptic peptides were analyzed by MALDI-TOF-MS to accurately measure their monoisotopic masses as well as determine their amino acid sequences. In order to facilitate fragmentation of the peptides they were N-terminally or C-terminally labeled. Several strains were investigated and anti-Pseudomonas IgY was immunoreactive against all of these strains, which strengthens its potential as a prophylactic treatment against PA. Flagellin was identified as the major antigen. Flagellin is the main protein of the flagella and is crucial for establishing infections in hosts as well as being involved in PA chemotaxis, motility, adhesion and inflammation. Furthermore, secreted flagellin elicits an inflammatory response. In conclusion, anti-Pseudomonas IgY binds flagellin, which may prevent PA infections in CF patients by hindering host invasion.
Nilsson
E
E
Department of Medical Sciences, Clinical Chemistry, Uppsala University, SE-751 85 Uppsala, Sweden. Elin.Nilsson@medsci.uu.se
Amini
A
A
Wretlind
B
B
Larsson
A
A
D000818:Animals; D015153:Blotting, Western; D002645:Chickens / Q000276:immunology*; D003550:Cystic Fibrosis / Q000150:complications*; D015180:Electrophoresis, Gel, Two-Dimensional; D005408:Flagellin / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000276:immunology; D011552:Pseudomonas Infections / Q000150:complications / Q000517:prevention & control*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
C016512:IgY; D007136:Immunoglobulins; D005408:Flagellin